HaloVax, LLC is a biopharmaceutical company and joint venture entity of Voltron Therapeutics, Inc. and Hoth Therapeutics, Inc. The joint venture was announced on March 23, 2020 (click here) and plans to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19. The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents. The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense (DoD). These same principles are being applied to developing a vaccine against the COVID-19 pandemic.

VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting. VaxCelerate offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.

VaxCelerate was created by Drs. Mark Poznansky, MD, PhD, and Jeffrey Gelfand, MD, who will continue to support its research and development, as COVID-19 has reached pandemic status. Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting as well as to help gather additional academic and clinical KOLs to serve on the SAB.


Our goal: Generate a safe and effective vaccine with animal data in 6 months or less.

HaloVax is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccine (SAV) to patients at risk for COVID-19 infection. We believe that our vaccine could be particularly effective and improve patient outcomes by engaging the immune system to identify and attack this pandemic infectious agent.

This technology has initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease. This was done with the support of the DoD. These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19

The SAV program has intellectual property surrounding composition of matter. Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc. The vaccine is >90% HSP70 and Aviden. Neoantigens are then incorporated to customize the vaccine.

We believe that the VaxCelerate technology has the potential to provide a differentiated approach to a COVID-19 vaccine.


July 8, 2020

Apr 22, 2020

Apr 15, 2020

Apr 2, 2020

Mar 23, 2020

Mar 23, 2020


Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.